Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Terns Pharmaceuticals, Inc.

$52.95

-0.02 (-0.04%)

C 47Pipeline Score Overvalued Biotech · Clinical
Market Cap
6.12 B
EPS
-1.03
P/E Ratio
-
Value Trade
336.12 M
SEC Financials
Q4 2025

  • Dilution Risk

    5%

  • R&D Expenses

    18.90 M

  • Operating CF

    -20.54 M

  • Total Assets

    1.03 B

  • Total Liabilities

    18.55 M

  • Equity

    1.01 B

  • D/E Ratio

    12,345

0.11 %
Week
0.36 %
1 Month
43.11 %
3 Month
208.66 %
6 Month
164.75 %
5 Year
212.39 %
All Time
Cash Data
Healthy

  • Cash Position

    1.02 B

  • Monthly Burn

    6.85 M

  • Runway

    145 mo

  • Burn Trend

    Decelerating

  • SEC Filing

    Mar 30, 2026
Overview
Volume
6.35 M
52 Week Range
2.66 - 53.19
% held by Insiders
8.73 %
% held by Institutions
100.41 %
Enterprise Value
5.10 B
Total Shares
115.57 M
Short %
4.92 %
Float Shares
112.45 M
Company Description
HQ: 1065 EAST HILLSDALE BLVD., SUI...
Employees:59
https://www.ternspharma.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%

FDA review of the new drug application for the treatment of example condition.

Read More
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Unlock the full Catalyst Timeline
Past FDA Catalysts & PDUFA Decisions
Date Drug Catalyst Stage Outcome Reaction Event Move % Best Trade %
2025-12-08
TERN-701 (novel investigational allosteric BCR::ABL1 inhibitor)
phase 1 data readout
Phase 1
—
–
–
–
2025-12-08
TERN-701 (novel investigational allosteric BCR::ABL1 inhibitor)
phase 1 data readout
Phase 1
—
–
–
–
2025-12-08
TERN-701 (novel investigational allosteric BCR::ABL1 inhibitor)
phase 1 data readout
Phase 1
—
–
–
–
Unlock 3 more historical catalysts
Drug Pipeline Intelligence
C47
Pipeline Score
$2.7B
Pipeline Value
Overvalued
Valuation Signal
5
Drugs Scored
0.4x
rNPV / MCap
Top 72%
Small Cap
(rank 257 of 913)
Percentile Rank
Terns Pharmaceuticals, Inc. carries a moderate pipeline score (47/100), with $4.1B risk-adjusted pipeline value, led by TERN-501 in NASH - Nonalcoholic Steatohepatitis (Phase 2).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
TERN-501
Small molecule		NASH - Nonalcoholic SteatohepatitisPhase 2NCT0541572223% $1.2B COMPLETED 162 - -Jul 1, 2023 -Mar 11, 2025
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
TERN-701
BreakthroughOrphan
chronic myeloid leukemia (CML)
Phase 1/2
2026-01-07

safety profile: 87% (55/63) of patients remained on treatment as of the data cutoff; no dose limiting toxicities: No dose-limiting toxicities were observed in dose escalation; grade 3 or higher teaes: Grade 3 or higher TEAEs were all less than 10%, most commonly neutropenia (8%) and thrombocytopenia (8%); mmr achievement rate: 75% (18/24) in evaluable patients enrolled at the recommended phase 2 dose range of >320mg QD

Read More

Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Read More
TERN-701
BreakthroughOrphan
chronic myeloid leukemia (CML)
Phase 1/2
2026-01-07

safety profile: 87% (55/63) of patients remained on treatment as of the data cutoff; no dose limiting toxicities: No dose-limiting toxicities were observed in dose escalation; grade 3 or higher teaes: Grade 3 or higher TEAEs were all less than 10%, most commonly neutropenia (8%) and thrombocytopenia (8%); mmr achievement rate: 75% (18/24) in evaluable patients enrolled at the recommended phase 2 dose range of >320mg QD

Read More

Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Read More
TERN-701
BreakthroughOrphan
chronic myeloid leukemia (CML)
Phase 1/2
2026-01-07

safety profile: 87% (55/63) of patients remained on treatment as of the data cutoff; no dose limiting toxicities: No dose-limiting toxicities were observed in dose escalation; grade 3 or higher teaes: Grade 3 or higher TEAEs were all less than 10%, most commonly neutropenia (8%) and thrombocytopenia (8%); mmr achievement rate: 75% (18/24) in evaluable patients enrolled at the recommended phase 2 dose range of >320mg QD

Read More

Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in TERN
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
TERN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How TERN ranks across every disease it competes in
Competitive Position is a premium feature
See how TERN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial